TECHNICAL PROGRAM - American Chemical Society Publications

117. Synthesis and SAR studies on novel
heteroaryl fused tetracyclic indole-diamide
compounds: Potent allosteric inhibitors
of the hepatitis C virus NS5B polymerase
enzyme. M. Ding,F.He,
X. Zheng, T. W. Hudyma, M. A. Poss,
J. F. Kadow, K. L. Rigat, Y. Wang,
R. Fridell, D. Qiu, M. Liu, S. Boss, M. Gao,
S. B. Roberts, R. G. Gentles
118. Synthesis and biological evaluation of
the selective inverse agonist PWZ-029 for
alpha 5 Bzr/GABA aergic receptor subtypes:
This ligand enhances cognition in
rhesus monkeys. S. K. Rallapalli,
C. Moran, J. K. Rowlett, J. M. Cook
119. Highly potent inhibitors of HCV NS3
protease. B. Venables, N. Sin, A. Wang,
L. Sun, D. Hernandez, A. Sheaffer,
M. Lee, D. Barry, J. Friborg, F. Yu,
J. Knipe, J. Sandquist, A. C. Good,
F. Mcphee, N. A. Meanwell, P. M. Scola
120. Design and synthesis of deuterated boceprevir
analogs with enhanced pharmacokinetic
properties. A. J. Morgan,
C. E. Masse, S. Nguyen, V. Uttamsingh,
R. Tung, S. Harbeson
121. Rational design, virtual screening, synthesis
and biological activity of donepezil-based
new acetylcholinesterase inhibitors.
S. Datta, D. Borkin, A. Rudnitskaya,
M. Torok, B. Torok
122. Application of small heterocyclic P3
caps in HCV NS3 protease inhibitors.
N. Sin, B. L. Venables, L. Sun,
A. X. Wang, S. Sit, Y. Chen, J. Chen,
Y. Han, A. C. Good, J. Friborg, D. Barry,
F. Yu, D. Hernandez, A. Sheaffer,
J. Knipe, F. McPhee, N. A. Meanwell,
P. M. Scola
123. Cyclic phosphate prodrugs of 2�deoxy-2�-fluoro-2�-C-methyl
nucleoside
analogs as inhibitors of HCV NS5B polymerase.
P. Reddy, D. Bao, W. Chang,
B. Chun, J. Du, D. Nagarathnam,
S. Rachakonda, B. S. Ross, H. Zhang,
S. Bansal, C. L. Espiritu, M. Keilman,
A. M. Lam, C. Niu, H. M. Steuer,
P. A. Furman, M. J. Otto, M. J. Sofia
124. Discovery of PSI-353661: A novel purine
nucleotide prodrug with improved in
vitro potency for the treatment of HCV infection.
W. Chang, D. Bao, B. Chun,
D. Nagarathnam, S. Rachakonda,
P. Reddy, B. S. Ross, H. Zhang,
S. Bansal, C. L. Espiritu, M. Keilman,
A. M. Lam, C. Niu, H. M. Steuer,
P. A. Furman, M. J. Otto, M. J. Sofia
125. Synthesis of novel, fluorinated P1 NS3
protease inhibitors of HCV. Y. Chen,
S. Sit, J. Chen, L. Sun, S. V. D’Andrea,
Z. Zheng, A. X. Wang, S. Hiebert,
M. Bowsher, A. Cocuzza, Q. Zhao,
D. Bilder, N. Sin, B. L. Venables,
D. Carini, B. Johnson, E. Mull,
D. Hernandez, A. K. Sheaffer,
H. Mulherin, F. Yu, J. O. Knipe,
K. Mosure, A. C. Good, R. Rajamani,
H. Klei, J. Friborg, V. Arora, Y. Shu,
X. Huang, L. Levesque, D. Li, J. Zhu,
S. Adam, F. McPhee, N. Meanwell,
P. M. Scola
126. Synthesis and SAR studies on highly
potent, novel, N,1-C2- phenyl-bridged
2-phenyl-indole-6-carboxamide based
hepatitis C virus NS5B inhibitors.
X. Zheng, T. W. Hudyma, M. Ding, F. He,
M. A. Poss, J. F. Kadow,
C. Chang, c. wan, M. R. Witmer, P. Morin,
D. M. Camac, S. Sheriff, B. R. Beno,
K. Rigat, Y. Wang, R. Fridell, J. Lemm,
D. Qiu, P. Liu, S. Voss, S. B. Roberts,
M. Gao, J. Knipe, R. G. Gentles
127. Isoquinoline tripeptides as HCV NS3
protease inhibitors. Z. B. Zheng,
A. X. Wang, D. Carini, A. Cocuzza,
S. Hiebert, M. Bowsher, Y. Chen, S. Sit,
L. Sun, F. Mcphee, J. Friborg, D. Barry,
F. Yu, D. Hernandez, J. Knipe,
R. Rajaman, H. Klei, A. Ng, B. Ma,
Q. Gao, N. A. Meanwell, P. M. Scola,
S. D’Andrea
128. SAR and mode of binding studies on a
series of N-benzyl-4-heteroaryl-1-(phenylsulfonyl)piperazine-2-carboxamides:
Potent inhibitors of the polymerase enzyme
(NS5B) of the hepatitis C virus.
R. G. Gentles, M. Ding, X. Zheng,
L. Chupak, M. A. Poss, C. Chang,
C. Wan, M. R. Witmer, P. Morin,
D. M. Camac, S. Sheriff, B. R. Beno,
K. Rigat, S. B. Roberts, M. Gao,
J. F. Kadow, J. Lemm, S. Voss, M. Liu,
L. Pelosi, Y. Wang
129. Development of novel carbohydrate
binding agents: A new class of potent antiviral
therapeutics. P. C. Trippier,
J. Balzarini, C. McGuigan
130. Synthesis and HIV-1 integrase inhibitory
activity of C2-C-linked heterocyclic-5-hydroxy-6-oxo-dihydropyrimidine-4-carboxamides.
B. Naidu, M. E. Sorenson,
M. Patel, Y. Ueda, J. Banville,
F. Beaulieu, S. Bollini, I. Dicker, H. Higley,
Z. Lin, L. Pajor, D. D. Parker, B. Terry,
M. Zheng, A. Martel, N. A. Meanwell,
M. Krystal, M. A. Walker
131. Design, synthesis and HIV-1 integrase
inhibitory activity associated with spirocycle-fused5-hydroxy-6-oxo-dihydropyrimidine-4-carboxamides.
B. Naidu,
M. E. Sorenson, J. D. Matiskella, Y. Ueda,
S. Bollini, I. Dicker, H. Higley, Z. Lin,
D. Wu, L. Pajor, D. D. Parker, B. Terry,
M. Zheng, N. A. Meanwell, M. Krystal,
M. A. Walker
132. Synthesis and evaluation of novel phosphoramidates
of acyclic nucleosides in
the bypass of the first phosphorylation
step mediated by the thymidine kinase.
D. Carta, C. McGuigan, C. Vanpouille,
L. Margolis, J. Balzarini
133. Study of C2-N-linked heterocyclic pyrimidin-6-oxa-5-hydroxy-4-carboxamide
derivatives as HIV integrase inhibitors.
M. Sorenson, B. Naidu, J. Matiskella,
T. Connolly, Y. Ueda, N. Meanwell,
S. Bollini, H. Samanta, B. Terry, Z. Lin,
I. Dicker, D. Parker, L. Pajor, M. Zheng,
M. Krystal, M. Walker
134. Design, synthesis and SAR study of
novel spiro aza-pyrimidinone HIV integrase
inhibitors. c. li, M. A. Walker,
Y. Ueda, J. Matiskella, Z. Lin, I. Dicker,
H. Samanta, B. Terry, H. Higley, S. Bollini,
M. Krystal, N. A. Meanwell
135. Discovery and preclinical evaluation of
the HIV integrase inhibitor BMS-727740.
M. A. Walker, J. Banville, B. Naidu,
M. Sorenson, R. Remillard, A. Martel,
Y. Ueda, T. Connolly, J. Weiss, C. Li,
A. Trehan, H. Wong, Z. Lin, I. Dicker,
H. Samanta, B. Terry, H. Scarnati,
C. Deminie, S. Bollini, M. Zheng,
A. Chimalakonda, L. Pajor, T. Philip,
D. Parker, M. Krystal, N. A. Meanwell
136. Towards the synthesis of novel boronates
as potential HIV-1 protease inhibitors.
J. L. Nye, D. R. Clayton,
M. S. McCammant, L. Fabry-Asztalos
137. Novel spirocyclobutyl- and spirocyclooxetanyl-pyrimidin-6-oxa-5-hydroxy-
4-carboxybenzylamides as potent HIV-1
integrase inhibitors. T. P. Connolly,
I. Dicker, M. Krystal, Z. Lin, J. Matiskella,
N. A. Meanwell, B. Naidu, L. Pajor,
M. Sorenson, B. Terry, Y. Ueda,
M. A. Walker, M. Zheng
138. Design, synthesis and structure-activity
relationships of novel dicamphanoyl-
2�,2�-dimethyldihydropyranochromone
(DCP) analogs as potent anti-HIV agents.
T. Zhou, C. Chen, Q. Shi, L. Huang,
P. Ho, K. Lee
139. HIV-1 protease inhibitors with a tertiaryalcohol-containing
transition-state mimic
and various P2/P1� substituents.
P. Öhrngren, X. Wu, J. K. Ekegren,
T. Unge, &. Rosenquist, B. Samuelsson,
M. Larhed
140. Design and synthesis of novel isatin derivatives
as potent anti-HIV agents.
R. K. Singh, G. Kumari, M. Yadav
141. Small molecules to target Mycobacterium
tuberculosis 1-Deoxy-D-xylulose-5phosphate
reducto-isomerase (MtbDxr).
E. R. Jackson, K. Kehn-Hall,
F. Kashanchi, H. I. Boshoff, C. S. Dowd
142. Synthesis and in silico studies of altered
DNA substrates as HIV RT inhibitors.
M. Yadav, G. Kumari, R. K. Singh
143. Synthesis of new antimalarial bi-drug
molecules. A. Jonet,
A. Dassonville-Klimpt, P. Sonnet
144. Motualevic acid analogs: Synthesis, antimicrobial
activity, and structure�activity
relationship (SAR) studies. P. Cheruku,
J. L. Keffer, C. A. Bewley
145. New bicyclic peptidomimetic inhibitors
of secreted aspartic proteinase 2 (SAP2)
for the treatment of drug-resistant Candida
albicans infections. A. Trabocchi,
C. Calugi, A. Cassone, R. Cauda,
A. Guarna
146. Quinolonimines as novel antimalarial
leads. T. Rodrigues, J. Gut,
P. J. Rosenthal, R. Moreira, R. Guedes,
D. Santos, F. Lopes
147. Discovery and development of the covalent
hydrates of trifluoromethylated
pyrazoles as riboflavin synthase inhibitors
with antitubercular activity. A. Talukdar,
A. Bacher, B. Illarionov, M. Fischer,
S. G. Franzblau, B. Wan, M. Cushman
148. Hybrid compounds targeting both liver
and blood stages of malaria parasites.
F. Lopes, R. Capela, R. Moreira,
P. J. Rosenthal, J. Gut, G. Cabal,
M. Prudêncio, M. Mota
149. Synthesis and antiviral activity of a second
generation of measles virus RNA-dependent
RNA polymerase activity inhibitors.
J. M. Ndungu, S. A. Krumm, A. Sun,
R. K. Plemper, J. P. Snyder
150. Design and synthesis of a sixteen million
member DNA-encoded library (DEL)
and discovery of potent Mycobacterium
tuberculosis (Mtb) InhA inhibitors.
C. P. Davie, P. A. Centrella,
G. K. O’Donovan, G. Evindar, H. O’Keefe,
A. M. Patel, M. A. Clark
151. Cell-based optimization of imidazolopiperazines
as new antimalarials. T. Wu,
A. Nagle, K. Kuhen, K. Henson,
R. Borboa, C. Francek, Z. Chen,
D. Plouffe, J. Chang, C. Li, T. Tuntland,
J. Isbell, M. Rottmann, E. Winzeler,
R. Glynne, D. C. Tully, A. K. Chatterjee
152. Modeling trypanosomal TOR kinase domains:
Implications for the design of antiparasitic
drugs. Z. Wang, C. E. Hubbard,
M. Ondrechen, M. P. Pollastri
153. High-speed synthesis of 3,6-disubstituted
pyrazolo[1,5-a]pyrimidines applied
to bone morphogenetic protein signaling
inhibitors. J. Liu,G.D.Cuny,P.B.Yu,
X. Xing, K. D. Bloch, R. T. Peterson
154. Total synthesis of YM-181741 for the
preparation of natural product-like
STAT3:STAT3 inhibitors. A. Misale,
D. Antonow, D. E. Thurston, G. Zinzalla
155. Tetrapodal Stat3 inhibitors offer potent
disruption of Stat3 in vitro and in whole
cell assays. B. D. Page, A. Schimmer,
J. Turkson, P. T. Gunning
156. NO-NSAIDs: Nitric oxide-releasing prodrugs
of non-steroidal anti-inflammatory
drugs with gastric-sparing properties.
K. V. Nemmani, N. Borhade, A. R. Pathan,
S. V. Mali, M. Karwa, S. S. P.,
V. Pamidiboina, M. Gund,
N. J. Deshmukh, P. Gaikwad, A. K. Jain,
J. J. Deshattiwar, S. Halder, D. C. Desai,
J. Mudgal, M. Dhiman, A. U. Burhan,
A. Sharma, N. P. Dubash, N. K. Mangu,
M. Dutta, G. Thakre, S. Goud,
D. Pacharne, L. Babu, S. Deshpande,
V. Nadar, S. Sharma, A. Satyam
157. Inhibition of CuZnSOD by low MW natural
products. J. S. Summers,
M. E. Arrington, M. R. Yost, J. Markley,
E. Parris, B. Hickman, J. Schmitt
158. Thiobenzimidazole-1-acetic acids as
CRTH2 antagonists. J. Pothier,
A. Fecher, M. Gude, K. Hilpert,
M. A. Riederer, X. Leroy, O. Peter,
H. Kletzl, C. Gnerre, R. Bravo,
S. Delahaye, L. Piali, F. Sylvie, H. Fretz
159. Development of SH2 domain proteomimetics
as potent disruptors of oncogenic
Stat3:Stat3 dimerization. J. A. Drewry,
P. T. Gunning
160. 1,3,6-substituted-4-aminopyrazolopyrimidines,
new potent inhibitors for phopholipase
D. J. Baffoe, A. M. Kulkarni,
V. Curry, B. Török, K. Stieglitz
161. Development of potent and selective
MMP inhibitors with a triazole zinc binding
group. J. Haas,A.M.Fryer,
S. W. Andrews, L. Huang, J. A. Josey,
S. Kragerud, Y. Marsh, J. P. Rizzi,
F. Sullivan
162. Reduction of hERG activity in (4,5,6,7tetrahydro-1H-indazolyl)ethanamines,
a
novel series of potent and selective S1P1
selective agonists. N. Aguilar,
M. Carrascal, M. Erra, S. Fonquerna,
L. Taboada, J. Alonso, B. Vidal,
N. Godessart, G. Tarrasón, T. Domenech,
C. Armengol, M. Córdoba, M. Sabaté,
D. Casals, M. Domínguez
163. Structure-activity relationship studies of
sphingosine kinase inhibitors. M. R. Raje,
Y. Kharel, K. R. Lynch, W. L. Santos
164. Amido-1,3,4-thiadiazole derivatives as
novel S1P1 selective agonists: From an
HTS hit to a sub-nanomolar, orally active
advanced lead. N. Aguilar, M. Mir,
P. Grima, M. López, N. Godessart,
G. Tarrasón, T. Domenech, D. Vilella,
C. Armengol, M. Córdoba, M. Sabaté,
D. Casals, M. Domínguez
165. Structure-based design of potent, conformationally
constrained, cell-permeable
STAT3 inhibitors. J. Chen,L.Bai,
Y. Zhao, D. Bernard,
Z. Nikolovska-Coleska, C. Gomez,
J. Zhang, H. Yi, S. Wang
166. Structure and activity relationships of
tartrate-based TACE inhibitors. D. Li,
J. V. Popovici-Muller, D. B. Belanger,
J. Caldwell, C. Dai, M. David,
V. M. Girijavallabhan, Z. Guo,
J. A. Kozlowski, B. J. Lavey, D. J. Lundell,
J. F. Lee, Z. Liu, R. Mazzola,
B. McKittrick, X. Niu, P. Orth, V. Madison,
J. Piwinski, R. Rizvi, K. E. Rosner,
B. Shankar, N. Shih, G. W. Shipps,
M. Siddiqui, J. Spitler, C. O. Strickland,
J. Sun, P. C. Ting, S. Chen, H. Vaccaro,
W. Yu, G. Zhou, Z. Zhu
167. New nNOS PDZ domain ligands and
their biological evaluation.
A. M. Perez-Lopez,
J. M. Cardenas-Maestre,
R. Salto-Gonzalez, M. Giron-Gonzalez,
J. Martinez-Lopez, T. de la Rubia-Nieto,
J. F. Dominguez-Seglar,
R. Sanchez-Martin, J. A. Gomez-Vidal
168. Synthesis of a series of nonpeptidic
thiochromanone-based thiosemicarbazone
analogs as inhibitors of cathepsin L.
J. Song, L. M. Jones,
K. Gaddale Devanna, E. S. Conner,
G. E. Chavarria, A. K. Charlton-Sevcik,
M. L. Trawick, B. G. Siim, D. J. Chaplin,
K. G. Pinney
169. Thiosemicarbazone derivatives of functionalized
tetralone, indanone, chromanone,
and 2,3-dihydroquinolinone
scaffolds as inhibitors of cathepsins L
and B. L. M. Jones,J.Song,
A. L. Johansen, A. K. Jantz,
G. E. Chavarria, A. K. Charlton-Sevcik,
M. Trawick, B. G. Siim, D. J. Chaplin,
K. G. Pinney
170. Rigidified 2-aminopyrimidines as histamine
H 4 receptor antagonists: Effects of
substitution about the rigidifying ring.
J. R. Koenig, H. Liu, I. Drizin, D. G. Witte,
T. L. Carr, A. M. Manelli, I. Milicic,
M. I. Strakhova, T. R. Miller,
T. A. Esbenshade, J. D. Brioni, M. Cowart
171. Design and synthesis of 3-alkylsulfonylmethylcyclohexylaminobenzamide-derived
inhibitors of CC chemokine receptor
2 (CCR2). M. G. Yang,D.G.Batt,
R. J. Cherney, S. Mandlekar, M. Cvijic,
Q. Zhao, J. C. Barrish, P. H. Carter
The official technical program
for the 240th National Meeting
is available at:
www.acs.org/boston2010
MEDI
TECH–75